Luca L.
- Country
- Italy
- Department
- Neurology
Research Overview
- Efficacy and Safety Evaluation of Riliprubart in Refractory Chronic Inflammatory Demyelinating Polyneuropathy: A Phase 3 Double-Blind, Placebo-Controlled Study
- Phase 3 Randomized Double-Blind Placebo-Controlled Study of Acoramidis Hydrochloride for Transthyretin Amyloidosis Prevention in Asymptomatic TTR Variant Carriers
- Evaluation of Safety, Tolerability, and Efficacy of Intravenous NVG-2089 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Patients
Data & Insights
Has run more than one trial at 64 of 104 partner sites.
Specializations
Neurological Disorders
The investigator specializes in treating Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), focusing on innovative therapeutic approaches for patients with treatment-resistant forms of the condition.
- Treatment-resistant CIDP management
- Novel therapeutic interventions
- Long-term disease monitoring
Their work extends to evaluating new treatment modalities for inflammatory neuropathies.
Immunological Studies
The investigator focuses on immune system diseases with particular attention to autoimmune neurological conditions and their treatment pathways.
- Autoimmune disorder therapeutics
- Immunological response assessment
- Treatment safety profiles
Their expertise includes evaluating immunomodulatory therapies for chronic conditions.
Rare Diseases
The investigator conducts research in Transthyretin Amyloidosis, particularly focusing on preventive treatments for asymptomatic carriers of pathogenic TTR variants.
- Early disease intervention
- Genetic variant analysis
- Preventive therapeutic strategies
Their work encompasses both cardiac and peripheral nervous system manifestations of amyloidosis.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.